Masakazu Abé

Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Hironobu Hashimoto, Masakazu Abé, Osamu Tokuyama et al. · The Lancet Oncology · 2019 · 218 citations

Drug Safety, Chemotherapy-induced Nausea, Pharmacology +7

A novel function of CD82/KAI-1 on E-cadherin-mediated homophilic cellular adhesion of cancer cells

Masakazu Abé, Tsuyoshi Sugiura, Miho Takahashi et al. · Cancer Letters · 2008 · 71 citations

Novel Function, Cell Interaction, Cell Adhesion +8

Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial

Masakazu Abé, Yasuyuki Hirashima, Yuka Kasamatsu et al. · Supportive Care in Cancer · 2015 · 68 citations

Cisplatin-based Chemotherapy, Medicine, Pharmacology +6

Suppression of haematopoiesis by IgG autoantibodies from patients with systemic lupus erythematosus (SLE)

H LIU, K Ozaki, Yumi Matsuzaki et al. · Clinical & Experimental Immunology · 1995 · 65 citations

Serum Inhibitor, Immunology, Blood Cell +20

Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice

Daichi Tamura, Noriaki Jinnouchi, Masakazu Abé et al. · International Journal of Clinical Oncology · 2020 · 47 citations

Urology, Real-world Clinical Practice, Oncology +7